Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - diclofenac potassium, quantity: 50 mg - tablet, sugar coated - excipient ingredients: colloidal anhydrous silica; calcium phosphate; magnesium stearate; maize starch; povidone; sodium starch glycollate; microcrystalline cellulose; iron oxide red; macrogol 8000; sucrose; purified talc; titanium dioxide - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - diclofenac sodium 50mg;  ;   - enteric coated tablet - 50 mg - active: diclofenac sodium 50mg     excipient: colloidal silicon dioxide hypromellose   silicon antifoam emulsion se2, enteric coat iron oxide red   iron oxide yellow   lactose monohydrate macrogol 8000 magnesium stearate maize starch methacrylic acid copolymer microcrystalline cellulose polyethylene glycol hydrogenated castor oil   povidone purified talc   sodium starch glycolate titanium dioxide   - treatment of: inflammatory and degenerative forms of rheumatism - rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and spondylarthritis, painful syndromes of the vertebral column, non-articular rheumatism; acute attacks of gout; post-traumatic and postoperative pain, inflammation, and swelling, e.g. following dental or orthopaedic surgery; painful and/or inflammatory conditions in gynaecology, e.g. primary dysmenorrhoea or adnexitis; as an adjuvant in severe painful inflammatory infections of the ear, nose, or throat, e.g. pharyngotonsillitis, otitis. in keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as appropriate. fever alone is not an indication.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - diclofenac sodium 50mg;   - suppository - 50 mg - active: diclofenac sodium 50mg   excipient: hard fat - · treatment of inflammatory and degenerative forms of rheumatism: rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and spondylarthritis, painful syndromes of the vertebral column, non-articular rheumatism.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - diclofenac 46.5mg (as free acid = 50mg diclofenac sodium);   - dispersible tablet - 50 mg - active: diclofenac 46.5mg (as free acid = 50mg diclofenac sodium)   excipient: colloidal silicon dioxide croscarmellose sodium hydrogenated castor oil microcrystalline cellulose purified talc sodium starch glycolate - latest regulatory activity

Canada - English - Health Canada

novartis pharmaceuticals canada inc - diclofenac potassium - tablet - 50mg - diclofenac potassium 50mg - other nonsteroidal antiimflammatory agents

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - diclofenac sodium - suppository - 50 mg - diclofenac sodium 50 mg

Canada - English - Health Canada

apotex inc - diclofenac potassium - tablet - 50mg - diclofenac potassium 50mg - other nonsteroidal antiimflammatory agents

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis consumer health australasia pty ltd - diclofenac potassium -

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - diclofenac sodium, quantity: 50 mg - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; macrogol 8000; purified talc; iron oxide red; colloidal anhydrous silica; iron oxide yellow; lactose monohydrate; magnesium stearate; povidone; titanium dioxide; peg-40 hydrogenated castor oil; hypromellose; sodium starch glycollate; methacrylic acid copolymer; maize starch; simethicone; sorbic acid; steareth-2 - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - diclofenac sodium, quantity: 50 mg - suppository, moulded - excipient ingredients: hydrogenated coco-glycerides; hard fat - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. short term (up to three days) treatment of post-operative pain in children.